申请人:Bayer Aktiengesellschaft
公开号:US05075311A1
公开(公告)日:1991-12-24
New substituted pyrido(2,3-d)pyrimidines of the formula ##STR1## can be prepared by reduction of corresponding pyrido(2,3-d)-pyrimidines which are substituted by a ketone radical, and subsequent hydrolysis, cyclization or hydrogenation. The new compounds can be used to inhibit HMG-CoA reductase.
新的取代的吡啶并[2,3-d]嘧啶的化学式为##STR1##,可通过还原相应的取代有酮基团的吡啶并[2,3-d]嘧啶,然后进行水解、环化或氢化制备。这些新化合物可用于抑制HMG-CoA还原酶。